Warning! GuruFocus detected
3 Severe warning signs
with DNA.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Ginkgo Bioworks Holdings Inc
NAICS : 541714
SIC : 2836
ISIN : US37611X1000
Compare
Compare
Traded in other countries / regions
DNA.USADNA.Mexico Index Membership
Russell 1000Russell 3000 IPO Date
2021-04-19Description
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.2 | |||||
| Equity-to-Asset | 0.52 | |||||
| Debt-to-Equity | 0.65 | |||||
| Debt-to-EBITDA | -0.97 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -6.28 | |||||
| Beneish M-Score | -2.86 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -22 | |||||
| 3-Year EBITDA Growth Rate | 44 | |||||
| 3-Year EPS without NRI Growth Rate | 47 | |||||
| 3-Year FCF Growth Rate | 6.9 | |||||
| 3-Year Book Growth Rate | -29.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 27.62 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 7.72 | |||||
| 9-Day RSI | 19.25 | |||||
| 14-Day RSI | 28.51 | |||||
| 3-1 Month Momentum % | 43.54 | |||||
| 6-1 Month Momentum % | 114.4 | |||||
| 12-1 Month Momentum % | -71.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.62 | |||||
| Quick Ratio | 5.62 | |||||
| Cash Ratio | 5.24 | |||||
| Days Inventory | 0.48 | |||||
| Days Sales Outstanding | 33.83 | |||||
| Days Payable | 146.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.5 | |||||
| Shareholder Yield % | -8.72 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 80.38 | |||||
| Operating Margin % | -214.82 | |||||
| Net Margin % | -240.94 | |||||
| FCF Margin % | -168.31 | |||||
| ROE % | -61.72 | |||||
| ROA % | -35.38 | |||||
| ROIC % | -59.92 | |||||
| 3-Year ROIIC % | 334.62 | |||||
| ROC (Joel Greenblatt) % | -103.07 | |||||
| ROCE % | -39.05 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.61 | |||||
| PB Ratio | 0.53 | |||||
| Price-to-Tangible-Book | 0.59 | |||||
| EV-to-EBIT | -0.51 | |||||
| EV-to-EBITDA | -0.57 | |||||
| EV-to-Forward-EBITDA | -26.93 | |||||
| EV-to-Revenue | 1.23 | |||||
| EV-to-Forward-Revenue | 7.7 | |||||
| EV-to-FCF | -0.74 | |||||
| Price-to-GF-Value | 0.23 | |||||
| Earnings Yield (Greenblatt) % | -196.08 | |||||
| FCF Yield % | -94.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:DNA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ginkgo Bioworks Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 227.043 | ||
| EPS (TTM) ($) | -10.68 | ||
| Beta | 1.26 | ||
| 3-Year Sharpe Ratio | -0.77 | ||
| 3-Year Sortino Ratio | -0.93 | ||
| Volatility % | 103.11 | ||
| 14-Day RSI | 28.51 | ||
| 14-Day ATR ($) | 1.102738 | ||
| 20-Day SMA ($) | 9.523 | ||
| 12-1 Month Momentum % | -71.05 | ||
| 52-Week Range ($) | 5.26 - 48 | ||
| Shares Outstanding (Mil) | 58.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ginkgo Bioworks Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ginkgo Bioworks Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ginkgo Bioworks Holdings Inc Frequently Asked Questions
What is Ginkgo Bioworks Holdings Inc(DNA)'s stock price today?
The current price of DNA is $7.00. The 52 week high of DNA is $48.00 and 52 week low is $5.26.
When is next earnings date of Ginkgo Bioworks Holdings Inc(DNA)?
The next earnings date of Ginkgo Bioworks Holdings Inc(DNA) is 2025-05-09 Est..
Does Ginkgo Bioworks Holdings Inc(DNA) pay dividends? If so, how much?
Ginkgo Bioworks Holdings Inc(DNA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers